DB
LCTX icon

Dmitry Balyasny’s Lineage Cell Therapeutics LCTX Stock Holding History

Dmitry Balyasny’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,362
Closed -$84.5K – 2554
2023
Q1 		$84.5K Buy
56,362
+32,622
+137% +$45.5K ﹤0.01% 2334
2022
Q4 		$27.8K Buy
+23,740
New +$29.9K ﹤0.01% 2438
2022
Q3 		– Sell
-10,432
Closed -$16K – 3069
2022
Q2 		$16K Buy
+10,432
New +$13.8K ﹤0.01% 2512
2021
Q2 		– Sell
-36,162
Closed -$85K – 2170
2021
Q1 		$85K Buy
+36,162
New +$86.8K ﹤0.01% 1648
2018
Q2 		– Sell
-34,416
Closed -$81K – 1984
2018
Q1 		$81K Buy
+34,416
New +$80.7K ﹤0.01% 1841
2015
Q4 		– Sell
-12,700
Closed -$31K – 1340
2015
Q3 		$31K Hold
12,700
– – ﹤0.01% 1106
2015
Q2 		$37K Buy
+12,700
New +$49.2K ﹤0.01% 1112

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dmitry Balyasny's LCTX Position: Q2 2023 in Review

Dmitry Balyasny sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 56,362 shares — an estimated $84.5K sold.

Dmitry Balyasny first reported a position in LCTX in Q2 2015 and held it in 7 quarters. The position peaked at $85K in Q1 2021. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • Dmitry Balyasny reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 56,362 Lineage Cell Therapeutics shares in Q2 2023, an estimated $84.5K.
  • Dmitry Balyasny first reported a position in Lineage Cell Therapeutics in Q2 2015 and held it in 7 quarters.
  • Dmitry Balyasny's Lineage Cell Therapeutics position peaked at $85K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.